Articles with "entity9s board" as a keyword



Photo by jareddrice from unsplash

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Sign Up to like & get
recommendations!
Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.1622.1622

Abstract: Introduction: Multiple studies have demonstrated that 40-50% of patients can maintain a treatment free remission (TFR) after having achieved a deep and sustained response to tyrosine kinase inhibitors (TKI) for the treatment of CML. However,… read more here.

Keywords: board directors; membership entity9s; entity9s board; directors advisory ... See more keywords
Photo by jareddrice from unsplash

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Sign Up to like & get
recommendations!
Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.1887.1887

Abstract: Background: Isatuximab (ISA) is an anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells through immune cell engagement and direct tumor targeting. We previously presented data from the dose-escalation cohort, and the… read more here.

Keywords: membership entity9s; funding; entity9s board; research funding ... See more keywords
Photo by jareddrice from unsplash

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

Sign Up to like & get
recommendations!
Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.2017.2017

Abstract: Introduction: In September 2013, the Spanish Myeloma Group (PETHEMA/GEM) activated a randomized phase III trial of induction therapy with VRD-GEM for 6 cycles (with extended full dose of lenalidomide from days 1 to 21), followed… read more here.

Keywords: board directors; advisory committees; membership entity9s; entity9s board ... See more keywords
Photo by jareddrice from unsplash

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Sign Up to like & get
recommendations!
Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.2585.2585

Abstract: Introduction: The PIM serine/threonine kinases (PIM1, PIM2 and PIM3) integrate multiple signaling networks and phosphorylate downstream substrates important for cell survival and proliferation (Abstract 5397, AACR 2015). Whereas the PIM kinase isozymes are differentially expressed… read more here.

Keywords: board directors; advisory committees; membership entity9s; entity9s board ... See more keywords
Photo by jareddrice from unsplash

Prognostic Impact of Tandem Autologous Stem Cell Transplantation (ASCT) in Different Response Subgroups after 1st ASCT

Sign Up to like & get
recommendations!
Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.3295.3295

Abstract: Background High dose (HD) chemotherapy with melphalan and autologous stem cell transplantation (ASCT) have been considered a standard treatment for newly diagnosed multiple myeloma (MM) patients for more than 30 years. Two-course (tandem) ASCT proved… read more here.

Keywords: board directors; response; membership entity9s; entity9s board ... See more keywords
Photo by jareddrice from unsplash

Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy

Sign Up to like & get
recommendations!
Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.413.413

Abstract: Introduction. In follicular lymphoma (FL), no prognostic index has been built based on a cohort of patients treated only with initial immunochemotherapy. Given the emergence of new biomolecular and metabolic prognostic factors in FL, an… read more here.

Keywords: entity9s board; honoraria; consultancy honoraria; membership entity9s ... See more keywords
Photo by jareddrice from unsplash

First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer

Sign Up to like & get
recommendations!
Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.4748.4748

Abstract: Introduction: Folate deficiency has been widely reported in association with several physiologic and pathologic conditions such as pregnancy, malnutrition, chronic hemolysis, inflammatory bowel disease, alcoholism, and cancer, as well as in conjunction with the administration… read more here.

Keywords: board directors; membership entity9s; entity9s board; directors advisory ... See more keywords
Photo by _louisreed from unsplash

In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

Sign Up to like & get
recommendations!
Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.819.819

Abstract: Introduction: Current therapies for relapsed/refractory (rel/ref) T-cell lymphomas (TCLs) induce responses in only 25-30% of patients (pts). Phosphoinositide-3-kinases (PI3K) play a pivotal role in cell signaling and PI3K isoforms have distinct roles in the development,… read more here.

Keywords: research; membership entity9s; entity9s board; research funding ... See more keywords